GSK announced that it has entered into an agreement with Chongqing Zhifei Biological Products, Ltd. to revise the terms on which Zhifei will commercialize GSK’s shingles vaccine, Shingrix, in mainland China. The revised agreement extends the original 3-year period (2024-2026) during which Zhifei has exclusive rights to import, distribute and co-promote the vaccine in mainland China for an additional 8 years through to 2034, with revised expected volumes. Under the revised agreement, Zhifei also agrees to engage exclusively with GSK to explore a potential collaboration, with an initial term of 10 years, on the commercialization of a respiratory syncytial virus (RSV) vaccine in mainland China, subject to regulatory approval of the vaccine.
Zhifei is the largest Chinese vaccine company by revenue, has an extensive network which covers more than 30,000 vaccination points across the country, and a strong track record of driving access to innovative vaccines in China.
Luke Miels, Chief Commercial Officer, GSK, said: “This revised agreement with Zhifei puts our collaboration on a sustainable footing, managing challenges in the macro environment in the near-term, and helping us to reach even more Chinese people with our innovative adult vaccines over the long-term.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!